Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (MRKR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mrkr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Marker Therapeutics, Inc. (MRKR) measures how much investors pay for each dollar of the company's trailing earnings. MRKR's current PE ratio of N/A is calculated by dividing its stock price of $1.46 by its TTM earnings per share of -$0.56.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Marker Therapeutics, Inc.You MRKR | $16M | N/A | — | -$0.56 |
 AEON Biopharma, Inc. AEON | $9M | N/A | — | -$3.95 |
 Bolt Biotherapeutics, Inc. BOLT | $9M | N/A | — | -$17.85 |
 Cellectar Biosciences, Inc. CLRB | $8M | N/A | — | -$8.35 |
 Cocrystal Pharma, Inc. COCP | $11M | N/A | — | -$0.78 |
 Evogene Ltd. EVGN | $5M | N/A | — | -$1.08 |
 Galecto, Inc. GLTO | $34M | N/A | — | -$143.51 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.79 | — | |
2024-12-31 FY2024 | — | $-1.20 | — | |
2023-12-31 FY2023 | — | $-0.94 | — | |
2022-12-31 FY2022 | — | $-3.58 | — | |
2021-12-31 FY2021 | — | $-5.47 | — | |
2020-12-31 FY2020 | — | $-6.10 | — | |
2019-12-31 FY2019 | — | $-4.70 | — | |
2018-12-31 FY2018 | — | $-77.51 | — | |
2017-12-31 FY2017 | — | $-11.62 | — | |
2016-12-31 FY2016 | — | $-0.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Marker Therapeutics, Inc. (MRKR) measures how much investors pay for each dollar of the company's trailing earnings. MRKR's current PE ratio of N/A is calculated by dividing its stock price of $1.46 by its TTM earnings per share of -$0.56.
Frequently asked questions
MRKR pe ratio · 6 questionsMRKR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.46 and TTM EPS of -$0.56. Data sourced from Financial Modeling Prep via MRKR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Marker Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09